雄激素受体信号作为急性髓系白血病干预的新靶点
研究利用MLL-AF9诱导的急性髓系白血病小鼠模型发现,高表达雄激素受体(AR)的白血病起始细胞(LICs)移植后所致疾病较低表达者更严重,且雌性LICs的AR表达显著高于雄性LICs,该差异仅限于LICs而不见于正常骨髓细胞。雌雄AML细胞分别通过高AR低配体与低AR高配体方式依赖AR信号,AR表达与EPHA7相关的PI3K/AKT/mTOR及SRC/HIF-1α通路相关。美国FDA已批准的前列腺癌药物ARN509(AR拮抗剂)与非那雄胺可诱导显著缓解并延长AML小鼠生存,在患者来源AML细胞及人源化NSG小鼠模型中亦显示促凋亡效应,支持抗雄激素治疗用于改善AML疗效的药物重定位研究。
要点
- 高表达AR的LICs移植后所致AML较低表达AR的LICs更严重。
- 雌性LICs的AR表达显著高于雄性LICs,差异仅限于LICs。
- ARN509与非那雄胺在AML小鼠中诱导显著缓解并延长生存。
核心结论
- 数据支持将抗雄激素治疗用于改善AML疗效的药物重定位研究。
研究设计与样本
- 研究使用MLL-AF9诱导的急性髓系白血病小鼠模型,将高或低表达AR的LICs移植入雄性 either 雌性受体鼠。
主要发现
- 高表达AR的LICs移植入雄性 either 雌性受体鼠后产生的疾病较低表达AR的LICs更严重。
- 雌性LICs的AR表达显著高于雄性LICs,该差异仅限于LICs,正常骨髓细胞中不存在。
- 雌性AML细胞表现为高AR水平伴低配体水平,雄性表现为低AR水平伴高配体水平。
- AR表达与EPHA7相关的PI3K/AKT/mTOR及SRC/HIF-1α通路相关。
- ARN509与非那雄胺使AML小鼠获得显著缓解并延长生存,在患者来源AML细胞及人源化NSG小鼠模型中显示促凋亡效应。
关键数值与推荐
- 美国FDA批准的两种前列腺癌药物:ARN509为AR拮抗剂,非那雄胺抑制产生双氢睾酮的通路。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In addition to their role in development, sex hormones and their cognate receptors play an important role in various malignancies. Using a murine model of human mixed lineage leukemia-acute leukemia fused gene from chromosome 9 (MLL-AF9)-induced acute myeloid leukemia (AML), we discovered that high androgen receptor (AR)-expressing leukemia initiating cells (LICs), when transferred into either male or female recipients, produced more severe disease than low AR-expressing LICs. AR expression was significantly increased in female LICs when compared with male LICs. This difference was confined to the LICs and was not present in normal bone marrow cells. AML cells from both sexes relied on AR signaling via different mechanisms; females had high AR levels with low ligand levels and males had low AR levels with high ligand levels. AR expression was linked to the ephrin type-A receptor 7 (EPHA7)-associated PI3K/AKT/mTOR and SRC/HIF-1α pathways. The use of the 2 United States Food and Drug Administration-approved drugs for prostate cancer, namely ARN509, an AR antagonist, and finasteride, which inhibits the pathway that produces dihydrotestosterone, led to significant remission with increased survival of the AML mice. ARN509 and finasteride also showed proapoptotic effects in patient-derived AML cells and in a humanized AML NOD scid gamma (NSG) mouse model. These data support a drug repurposing effort for the use of antiandrogen therapy to improve the efficacy of AML treatments.
引用
- Qian F, Sarkar D, Arner BE, et al. Androgen receptor signaling as a new target for intervention in acute myeloid leukemia. Blood Adv. 2025. PMID: 40991369. doi:10.1182/bloodadvances.2024012639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。